Parenteral ferumoxytol interaction with magnetic resonance imaging: A case report, review of the literature and advisory warning

Insights into Imaging

Volumn 4, Issue 4, 2013, Pages 509-512

  Schieda, Nicola ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Ferumoxytol; Gadolinium; Iron; Magnetic resonance imaging; Small iron oxide particle

Indexed keywords

EID: 84881047485     PISSN: None     EISSN: 18694101     Source Type: Journal    
DOI: 10.1007/s13244-013-0262-8     Document Type: Review

References (7)

1. Health Canada (2012) Summary basis of decision (SBD) for FERAHEME. Health Canada, Ottawa. Available via: http://www. hc-sc. gc. ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2012_feraheme_133250-eng. php. Accessed 26 June 2012.
2. Lu M, Cohen MH, Rieves D, Pazdur R (2010) FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 85: 315-319.
3. European Medicines Agency (2012) Rienso: CHMP summary of positive opinion for Rienso. European Medicines Agency, London. Available via: http://www. ema. europa. eu/ema/index. jsp?curl=pages/medicines/human/medicines/002215/human_med_001569. jsp&mid=WC0b01ac058001d124. Accessed 20 April 2012.
4. Albaramki J, Hodson EM, Craig JC, Webster AC (2012) Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 1, CD007857.
5. McCullough BJ, Kolokythas O, Maki JH, Green DE (2012) Ferumoxytol in clinical practice: implications for MRI. J Magn Reson Imaging 36(4): 1-4.
6. Neuwelt EA, Hamilton BE, Varallyay CG, Rooney WR, Edelmen RD, Jacobs PM, Watnick SG (2009) Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis? Kidney Int 75(5): 465-474.
7. Storey P, Lim RP, Chandarana H, Rosenkrantz AB, Kim D, Stoffel DR, Lee VS (2012) MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults. Invest Radiol 47(12): 717-724.